Abdulrahman I. Alshaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Abdulrahman I. Alshaya has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Omar A. Almohammed
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
6 shared publications - Khalid Al Sulaiman
College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
4 shared publications - Mohammed Alrashed
Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh 11426, Saudi Arabia
4 shared publications Hisham A. Badreldin
Department of Pharmaceutical Care Services, King Abdulaziz Medical City, Riyadh, Saudi Arabia
3 shared publicationsKhalid Bin Saleh
Department of Pharmacy Practice, College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia
3 shared publications- Majed S. Al Yami
Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh 14611, Saudi Arabia
3 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-10
Colistin Therapy for Urinary Tract Infections Due to Multidrug-Resistant Bacteria: Experience at a Tertiary Academic Medical Center
Background: Urinary tract infections (UTIs) caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) present increasing therapeutic challenges, especially in regions with limited access to novel β-lactam/β-lactamase inhibitors. Colistin remains a salvage therapy in such cases; however, data describing its real-world efficacy and nephrotoxicity in urinary infections are limited. Methods: We conducted a retrospective cohort study of adult patients who received intravenous colistin (colistimethate sodium) for culture-confirmed UTIs at a tertiary academic medical center in Riyadh, Saudi Arabia. The primary outcome was colistin-induced acute kidney injury (AKI), defined as an increase in serum creatinine of ≥ 26 μmol/L from baseline per the AKIN creatinine criterion. Secondary outcomes included microbiologic failure, clinical failure, and in-hospital mortality. Multivariable logistic regression was used to identify independent predictors of AKI. Results: Among 102 patients, the median age was 80 years (IQR, 72– 84), and 46% were male. Klebsiella pneumoniae (44.9%) and Pseudomonas aeruginosa (20.4%) were the most common pathogens. Over half (52%) were exposed to concomitant nephrotoxic agents. Colistin-induced AKI occurred in 15 patients (14.7%). Chronic kidney disease was more frequent among those who developed AKI (73% vs. 26%, p< 0.001); however, no independent predictors were identified in multivariable analysis. In a sensitivity analysis using CKD as a binary covariate, CKD was independently associated with AKI (adjusted OR 19.17; 95% CI, 3.03– 121.30; p=0.002). Clinical failure occurred in 12.7% and microbiologic failure in 2.9% of patients. Conclusion: In this cohort of patients with MDR-GNB UTIs, intravenous colistin was associated with favorable clinical and microbiological outcomes. The observed incidence of AKI was lower than previously reported in the literature, though this should be interpreted cautiously given the small number of events and the high prevalence of baseline renal impairment and nephrotoxic co-exposures. The infographic is divided into three sections: study population, treatment and outcomes. The study population section describes patients with multidrug-resistant gram-negative urinary tract infections, totaling 102 individuals. The median age is 80 years, with 33.3 percent having chronic kidney disease and 52.0 percent exposed to nephrotoxic agents. The treatment section details intravenous colistin, specifically colistimethate sodium (CMS). The median duration of treatment is 10 days, with a median loading dose of 4 mg per kg (range 2.5 to 5) and a median maintenance dose of 2.9 mg per kg per day (range 1.95 to 4.35). The outcomes section lists clinical failure at 12.7 percent, microbiological failure at 2.9 percent, culture negative results in 5 days, afebrile status in 1 day and colistin-induced acute kidney injury at 14.7 percent.Infographic on study population, treatment and outcomes of intravenous colistin for urinary tract infections.
- 1 May 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-10
Open AccessColistin Therapy for Urinary Tract Infections Due to Multidrug-Resistant Bacteria: Experience at a Tertiary Academic Medical Center
Background: Urinary tract infections (UTIs) caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) present increasing therapeutic challenges, especially in regions with limited access to novel β-lactam/β-lactamase inhibitors. Colistin remains a salvage therapy in such cases; however, data describing its real-world efficacy and nephrotoxicity in urinary infections are limited. Methods: We conducted a retrospective cohort study of adult patients who received intravenous colistin (colistimethate sodium) for culture-confirmed UTIs at a tertiary academic medical center in Riyadh, Saudi Arabia. The primary outcome was colistin-induced acute kidney injury (AKI), defined as an increase in serum creatinine of ≥ 26 μmol/L from baseline per the AKIN creatinine criterion. Secondary outcomes included microbiologic failure, clinical failure, and in-hospital mortality. Multivariable logistic regression was used to identify independent predictors of AKI. Results: Among 102 patients, the median age was 80 years (IQR, 72– 84), and 46% were male. Klebsiella pneumoniae (44.9%) and Pseudomonas aeruginosa (20.4%) were the most common pathogens. Over half (52%) were exposed to concomitant nephrotoxic agents. Colistin-induced AKI occurred in 15 patients (14.7%). Chronic kidney disease was more frequent among those who developed AKI (73% vs. 26%, p< 0.001); however, no independent predictors were identified in multivariable analysis. In a sensitivity analysis using CKD as a binary covariate, CKD was independently associated with AKI (adjusted OR 19.17; 95% CI, 3.03– 121.30; p=0.002). Clinical failure occurred in 12.7% and microbiologic failure in 2.9% of patients. Conclusion: In this cohort of patients with MDR-GNB UTIs, intravenous colistin was associated with favorable clinical and microbiological outcomes. The observed incidence of AKI was lower than previously reported in the literature, though this should be interpreted cautiously given the small number of events and the high prevalence of baseline renal impairment and nephrotoxic co-exposures. The infographic is divided into three sections: study population, treatment and outcomes. The study population section describes patients with multidrug-resistant gram-negative urinary tract infections, totaling 102 individuals. The median age is 80 years, with 33.3 percent having chronic kidney disease and 52.0 percent exposed to nephrotoxic agents. The treatment section details intravenous colistin, specifically colistimethate sodium (CMS). The median duration of treatment is 10 days, with a median loading dose of 4 mg per kg (range 2.5 to 5) and a median maintenance dose of 2.9 mg per kg per day (range 1.95 to 4.35). The outcomes section lists clinical failure at 12.7 percent, microbiological failure at 2.9 percent, culture negative results in 5 days, afebrile status in 1 day and colistin-induced acute kidney injury at 14.7 percent.Infographic on study population, treatment and outcomes of intravenous colistin for urinary tract infections.
- Open Access
- 18 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1485357
Re-starting or initiating guideline-recommended hypoglycemic agents for patients admitted with hyperglycemic crisis
Introduction: Hyperglycemic crises, such as diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), are life-threatening complications of diabetes. This study aimed to assess the impact of early initiation of non-insulin hypoglycemic agents on glycemic variation following acute management of DKA/HHS.Research design and methods: This retrospective cohort study was conducted at King Abdulaziz Medical City and King Abdullah Specialized Children Hospital in Riyadh, Saudi Arabia. Patients with diabetes mellitus admitted between January 2015 and December 2023 were included if they had a confirmed diagnosis of DKA or HHS and received any non-insulin hypoglycemic agents after receiving acute care management. The primary outcome was to assess the impact of early initiation (defined as less than 24–48 h) of non-insulin hypoglycemic agents following acute management of DKA/HHS in controlling glycemic variation by measuring delta blood glucose “BG,” with secondary outcomes including hypoglycemia incidence, correctional insulin requirements, predictors for hospital length of stay (LOS), 90-day mortality, and hospital readmissions. Data was adjudicated by a separate clinician. Statistical analysis was performed using SPSS (IBM, Armonk, NY).Results: Out of 1,483 screened patients, 137 were included, experiencing a total of 226 hyperglycemic events. During hospitalization, 42.9% of patients were transitioned to oral hypoglycemic agents within 4 days. Transitioning to oral hypoglycemic medications resulted in a significant reduction in BG levels. Early re/initiation of hypoglycemic agents was strong predictor for shorter hospital LOS and lower 90-day mortality rate (2.1% vs. 10.1%, p-value = 0.02). There were no other significant outcomes.Conclusion: The study suggests that early initiation of non-insulin hypoglycemic results in similar delta BG compared to late initiation following acute management of DKA and HHS. The findings indicate that early transitioning to non-insulin hypoglycemic agents is associated with a lower 90-day mortality rate after acute management of DKA/HHS and a strong predictor for shorter hospital LOS. Further research, including randomized controlled trials, is recommended to validate these findings and explore long-term effects on mortality and clinical outcomes.
- 18 August 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1485357
Open AccessRe-starting or initiating guideline-recommended hypoglycemic agents for patients admitted with hyperglycemic crisis
Introduction: Hyperglycemic crises, such as diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), are life-threatening complications of diabetes. This study aimed to assess the impact of early initiation of non-insulin hypoglycemic agents on glycemic variation following acute management of DKA/HHS.Research design and methods: This retrospective cohort study was conducted at King Abdulaziz Medical City and King Abdullah Specialized Children Hospital in Riyadh, Saudi Arabia. Patients with diabetes mellitus admitted between January 2015 and December 2023 were included if they had a confirmed diagnosis of DKA or HHS and received any non-insulin hypoglycemic agents after receiving acute care management. The primary outcome was to assess the impact of early initiation (defined as less than 24–48 h) of non-insulin hypoglycemic agents following acute management of DKA/HHS in controlling glycemic variation by measuring delta blood glucose “BG,” with secondary outcomes including hypoglycemia incidence, correctional insulin requirements, predictors for hospital length of stay (LOS), 90-day mortality, and hospital readmissions. Data was adjudicated by a separate clinician. Statistical analysis was performed using SPSS (IBM, Armonk, NY).Results: Out of 1,483 screened patients, 137 were included, experiencing a total of 226 hyperglycemic events. During hospitalization, 42.9% of patients were transitioned to oral hypoglycemic agents within 4 days. Transitioning to oral hypoglycemic medications resulted in a significant reduction in BG levels. Early re/initiation of hypoglycemic agents was strong predictor for shorter hospital LOS and lower 90-day mortality rate (2.1% vs. 10.1%, p-value = 0.02). There were no other significant outcomes.Conclusion: The study suggests that early initiation of non-insulin hypoglycemic results in similar delta BG compared to late initiation following acute management of DKA and HHS. The findings indicate that early transitioning to non-insulin hypoglycemic agents is associated with a lower 90-day mortality rate after acute management of DKA/HHS and a strong predictor for shorter hospital LOS. Further research, including randomized controlled trials, is recommended to validate these findings and explore long-term effects on mortality and clinical outcomes.
- Open Access
- 14 January 2025
- Published by The Korean Society of Emergency Medicine in Clinical and Experimental Emergency Medicine
- Vol. 12 (3) , 212-222
Comparison of 4-factor fixed dose versus 4-factor weight-based dose prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
The objective of this systematic review and meta-analysis is to evaluate the efficacy, safety, time to INR reversal, total volume of 4-factor prothrombin complex concentrate (PCC) administered of fixed-dose versus weight-based dosing strategies in patients requiring urgent warfarin reversal, with specific focus on clinical outcomes such as hemostatic efficacy, thromboembolic events, and mortality rates. A comprehensive systematic review was conducted using the PubMed, Embase, and Cochrane databases from inception through October 2023. We searched for randomized clinical trials or observational studies that compared efficacy or safety outcomes of fixed-dose vs. variable 4-PCC dose in adult patients. A total of fourteen studies were included. The overall use of fixed-dose 4-PCC was associated with a lower likelihood of reaching the INR goal (RR = 0.84, 95% CI 0.80 - 0.89) and a significantly higher proportion of patients (169 out of 651 [26%]) required an additional dose of 4-PCC compared to the variable-dose group. The rate of mortality (RR = 0.85, 95% CI 0.70 - 1.03) and thromboembolic events (RR = 1.27, 95% CI 0.65 - 2.45) were similar between the two treatment groups. This systematic review and meta-analysis showed that variable dosing of 4-PCC more successfully achieves the target INR for warfarin reversal compared to fixed dosing. However, both dosing strategies have similar mortality and thromboembolic rates. While fixed dosing offers a simpler approach, it may require additional dosing. Future studies should focus on optimizing dosing strategies to balance efficacy, safety, and practicality in various clinical scenarios.
- 14 January 2025
- Published by The Korean Society of Emergency Medicine in Clinical and Experimental Emergency Medicine
- Vol. 12 (3) , 212-222
Open AccessComparison of 4-factor fixed dose versus 4-factor weight-based dose prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
The objective of this systematic review and meta-analysis is to evaluate the efficacy, safety, time to INR reversal, total volume of 4-factor prothrombin complex concentrate (PCC) administered of fixed-dose versus weight-based dosing strategies in patients requiring urgent warfarin reversal, with specific focus on clinical outcomes such as hemostatic efficacy, thromboembolic events, and mortality rates. A comprehensive systematic review was conducted using the PubMed, Embase, and Cochrane databases from inception through October 2023. We searched for randomized clinical trials or observational studies that compared efficacy or safety outcomes of fixed-dose vs. variable 4-PCC dose in adult patients. A total of fourteen studies were included. The overall use of fixed-dose 4-PCC was associated with a lower likelihood of reaching the INR goal (RR = 0.84, 95% CI 0.80 - 0.89) and a significantly higher proportion of patients (169 out of 651 [26%]) required an additional dose of 4-PCC compared to the variable-dose group. The rate of mortality (RR = 0.85, 95% CI 0.70 - 1.03) and thromboembolic events (RR = 1.27, 95% CI 0.65 - 2.45) were similar between the two treatment groups. This systematic review and meta-analysis showed that variable dosing of 4-PCC more successfully achieves the target INR for warfarin reversal compared to fixed dosing. However, both dosing strategies have similar mortality and thromboembolic rates. While fixed dosing offers a simpler approach, it may require additional dosing. Future studies should focus on optimizing dosing strategies to balance efficacy, safety, and practicality in various clinical scenarios.
- Open Access
- 31 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6548
Impact of Hyperuricemia on Clinical Outcomes in Sepsis Patients: A Retrospective Cohort Study
Background: Hyperuricemia has been linked to various adverse clinical outcomes. Data on the clinical outcomes and the relationship between hyperuricemia and sepsis remain limited. The aim of this study was to evaluate the impact of hyperuricemia on clinical outcomes in sepsis patients and to identify whether it can predict the mortality in this patient population. Methods: This was a retrospective cohort study of adult patients with sepsis admitted to the intensive care unit (ICU) from 1 January 2021 to 31 December 2023. The patients were divided into hyperuricemia and non-hyperuricemia groups. Hyperuricemia was defined as a serum uric acid level > 416.4 µmol/L (7.0 mg/dL) in males or >357.0 µmol/L (6.0 mg/dL) in females based on the first serum uric acid reading within 24 h of ICU admission. The primary outcome of this study was ICU mortality. Secondary outcomes included in-hospital mortality, progression to septic shock, and ICU and hospital lengths of stay (LOSs). Results: A total of 599 patients were included in the study. Among these, 303 were in hyperuricemia group, while 296 were in the non-hyperuricemia group. The incidence of ICU and in-hospital mortality was higher in the hyperuricemia group compared to the non-hyperuricemia group (26.7% vs. 18.9% (p < 0.001) and 34.7% vs. 19.3% (p < 0.001), respectively). After adjusting for cofounders, hyperuricemia was not a predictor of ICU mortality (OR 1.52, 95% CI 0.95–2.43, p = 0.083). Most secondary outcomes were similar between the groups. However, the hyperuricemia group had a higher incidence of progression to septic shock (67.3% vs. 50.7%, p < 0.001), and hospital LOS was significantly longer in the hyperuricemia group (384 vs. 264 h, p = 0.004). Conclusions: Our findings demonstrated that hyperuricemia in sepsis patients was associated with worse clinical outcomes such as higher ICU and hospital mortality. Moreover, there was a higher incidence of septic shock progression and longer hospital LOS. The other outcomes were not statistically significantly different. Further prospective research is warranted to confirm these findings.
- 31 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6548
Open AccessImpact of Hyperuricemia on Clinical Outcomes in Sepsis Patients: A Retrospective Cohort Study
Background: Hyperuricemia has been linked to various adverse clinical outcomes. Data on the clinical outcomes and the relationship between hyperuricemia and sepsis remain limited. The aim of this study was to evaluate the impact of hyperuricemia on clinical outcomes in sepsis patients and to identify whether it can predict the mortality in this patient population. Methods: This was a retrospective cohort study of adult patients with sepsis admitted to the intensive care unit (ICU) from 1 January 2021 to 31 December 2023. The patients were divided into hyperuricemia and non-hyperuricemia groups. Hyperuricemia was defined as a serum uric acid level > 416.4 µmol/L (7.0 mg/dL) in males or >357.0 µmol/L (6.0 mg/dL) in females based on the first serum uric acid reading within 24 h of ICU admission. The primary outcome of this study was ICU mortality. Secondary outcomes included in-hospital mortality, progression to septic shock, and ICU and hospital lengths of stay (LOSs). Results: A total of 599 patients were included in the study. Among these, 303 were in hyperuricemia group, while 296 were in the non-hyperuricemia group. The incidence of ICU and in-hospital mortality was higher in the hyperuricemia group compared to the non-hyperuricemia group (26.7% vs. 18.9% (p < 0.001) and 34.7% vs. 19.3% (p < 0.001), respectively). After adjusting for cofounders, hyperuricemia was not a predictor of ICU mortality (OR 1.52, 95% CI 0.95–2.43, p = 0.083). Most secondary outcomes were similar between the groups. However, the hyperuricemia group had a higher incidence of progression to septic shock (67.3% vs. 50.7%, p < 0.001), and hospital LOS was significantly longer in the hyperuricemia group (384 vs. 264 h, p = 0.004). Conclusions: Our findings demonstrated that hyperuricemia in sepsis patients was associated with worse clinical outcomes such as higher ICU and hospital mortality. Moreover, there was a higher incidence of septic shock progression and longer hospital LOS. The other outcomes were not statistically significantly different. Further prospective research is warranted to confirm these findings.
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in Saudi Journal of Clinical Pharmacy
- Vol. 3 (4) , 179-185
Artificial Intelligence Integration and Data Governance in Pharmacy and the Healthcare sector: A Position Statement on Behalf of the Saudi Society of Clinical Pharmacy (SSCP) and the Saudi Health Informatics Pharmacists (SHIP)
The Saudi Society of Clinical Pharmacy (SSCP) and the Saudi Health Informatics Pharmacists (SHIP) collaborated to develop a position statement on the integration of artificial intelligence (AI) and data governance in the pharmacy practice and the healthcare sector. The SSCP and the SHIP have established a focused group dedicated to creating a comprehensive overview and formulating the position paper. Through a modified Delphi method of two rounds, the task force developed 12 key recommendations with a≥80% consensus rate covering a wide range of areas, including policy development, regulatory frameworks, education and training, ethical considerations, data governance, and patient privacy, to create an environment that supports the responsible and effective utilization of AI in pharmacy practice. This position statement calls on stakeholders in the pharmacy profession and the healthcare sector to embrace AI as a transformative tool while ensuring that ethical principles, patient safety, and the promotion of optimal healthcare outcomes guide its implementation. The SSCP and SHIP are addressing these crucial aspects as an opportunity for Saudi Arabia to spearhead advancements in AI integration in pharmacy and contribute to the global progress in healthcare innovation.
- 1 October 2024
- Published by Wolters Kluwer Health in Saudi Journal of Clinical Pharmacy
- Vol. 3 (4) , 179-185
Open AccessArtificial Intelligence Integration and Data Governance in Pharmacy and the Healthcare sector: A Position Statement on Behalf of the Saudi Society of Clinical Pharmacy (SSCP) and the Saudi Health Informatics Pharmacists (SHIP)
The Saudi Society of Clinical Pharmacy (SSCP) and the Saudi Health Informatics Pharmacists (SHIP) collaborated to develop a position statement on the integration of artificial intelligence (AI) and data governance in the pharmacy practice and the healthcare sector. The SSCP and the SHIP have established a focused group dedicated to creating a comprehensive overview and formulating the position paper. Through a modified Delphi method of two rounds, the task force developed 12 key recommendations with a≥80% consensus rate covering a wide range of areas, including policy development, regulatory frameworks, education and training, ethical considerations, data governance, and patient privacy, to create an environment that supports the responsible and effective utilization of AI in pharmacy practice. This position statement calls on stakeholders in the pharmacy profession and the healthcare sector to embrace AI as a transformative tool while ensuring that ethical principles, patient safety, and the promotion of optimal healthcare outcomes guide its implementation. The SSCP and SHIP are addressing these crucial aspects as an opportunity for Saudi Arabia to spearhead advancements in AI integration in pharmacy and contribute to the global progress in healthcare innovation.
- Open Access
- 12 July 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (28) , e38959
Use of antiepileptic medications for seizures’ prevention during subarachnoid hemorrhage: A retrospective observational study
The use of prophylactic antiepileptic drugs (AEDs) post-subarachnoid hemorrhage (SAH), particularly aneurysmal SAH, is controversial, with limited data available. This has led the new American Heart Association/American Stroke Association (AHA/ASA) guidelines to recommend against using AEDs. This study is aimed at determining whether the use of AEDs for primary prophylaxis is effective in reducing the incidence of seizures post-SAH. A retrospective observational study was conducted utilizing a reviewing chart for the period starting from June 2015 to the end of 2021. The reviews were conducted in the acute care areas of 2 tertiary hospitals primarily to assess the efficacy of AEDs against seizures in patients with SAH (particularly aneurysmal SAH). This was done by comparing the occurrence of early, late, and overall incidence of seizures between patients who received AEDs versus those who did not. Of the 62 patients, who mostly presented with aneurysmal SAH (71%), 42 received AEDs and 20 did not. Mostly, the baseline characteristics between the 2 groups were comparable. A few patients on AEDs developed early (n = 4/38), late (n = 3/29), and overall seizures (n = 6/33), whereas no early, late, or overall incidence of seizures was presented in the group who did not receive AEDs. However, this difference showed no significance ( P > .05). The subjects who were given AEDs showed significantly longer hospital stays (42.11 ± 51.43 vs 14.10 ± 7.17; P = .002) and higher mortality rates (7/11 vs 0/11; P = .026). For all patients who received AEDs for prophylaxis, the overall incidence of seizures was negatively associated with the Glasgow coma scale (OR: 0.798; 95% CI 0.657–0.978; P = .022). Our findings support the 2023 AHA/ASA guideline recommendation to avoid using routine AEDs for prophylaxis for all SAH patients. Proper and careful stratification methods should be implemented in each given scenario.
- 12 July 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (28) , e38959
Open AccessUse of antiepileptic medications for seizures’ prevention during subarachnoid hemorrhage: A retrospective observational study
The use of prophylactic antiepileptic drugs (AEDs) post-subarachnoid hemorrhage (SAH), particularly aneurysmal SAH, is controversial, with limited data available. This has led the new American Heart Association/American Stroke Association (AHA/ASA) guidelines to recommend against using AEDs. This study is aimed at determining whether the use of AEDs for primary prophylaxis is effective in reducing the incidence of seizures post-SAH. A retrospective observational study was conducted utilizing a reviewing chart for the period starting from June 2015 to the end of 2021. The reviews were conducted in the acute care areas of 2 tertiary hospitals primarily to assess the efficacy of AEDs against seizures in patients with SAH (particularly aneurysmal SAH). This was done by comparing the occurrence of early, late, and overall incidence of seizures between patients who received AEDs versus those who did not. Of the 62 patients, who mostly presented with aneurysmal SAH (71%), 42 received AEDs and 20 did not. Mostly, the baseline characteristics between the 2 groups were comparable. A few patients on AEDs developed early (n = 4/38), late (n = 3/29), and overall seizures (n = 6/33), whereas no early, late, or overall incidence of seizures was presented in the group who did not receive AEDs. However, this difference showed no significance ( P > .05). The subjects who were given AEDs showed significantly longer hospital stays (42.11 ± 51.43 vs 14.10 ± 7.17; P = .002) and higher mortality rates (7/11 vs 0/11; P = .026). For all patients who received AEDs for prophylaxis, the overall incidence of seizures was negatively associated with the Glasgow coma scale (OR: 0.798; 95% CI 0.657–0.978; P = .022). Our findings support the 2023 AHA/ASA guideline recommendation to avoid using routine AEDs for prophylaxis for all SAH patients. Proper and careful stratification methods should be implemented in each given scenario.
- 14 March 2024
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 52 (4) , e203-e204
How Reliable Are Serum Levetiracetam Levels to Be Used as a Primary Endpoint?
- 14 March 2024
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 52 (4) , e203-e204
How Reliable Are Serum Levetiracetam Levels to Be Used as a Primary Endpoint?
- Open Access
- 1 November 2023
- Published by Taylor & Francis in Journal of Multidisciplinary Healthcare
- Vol. ume 16, 3227-3234
Characteristics of Critical Care Pharmacy Services in Saudi Arabia
Purpose: Critical care pharmacists (CCPs) in intensive care units (ICUs) are associated with improved patient outcomes, reduced adverse events (ADEs), and reduced mortality rates. This study aimed to describe the activities and pharmacy services provided by CCP in ICUs in hospitals in Saudi Arabia (SA). Methods: In this cross-sectional prospective study, a questionnaire was electronically sent to CCPs practicing in SA between September 2022 and January 2023. A modified version of a previously published and validated survey was sent to the Saudi Critical Care and Emergency Specialty Network. The questionnaire focused on four CCP activities: clinical, educational, scholarly, and administrative. The level of services was similarly classified into three domains: fundamental, optimal, and desirable. The responses were analyzed using descriptive statistics. Results: The study surveyed 44 CCPs in SA, with a response rate of 52.3%. These CCPs were predominantly located in the central (47.8%) and eastern (30.4%) regions. Hospitals’ ICU bed capacity ranged from 10 to 100, with 82% reporting mixed medical and surgical ICUs. Most CCPs had 4– 10 years of critical care experience, and 60% held advanced degrees, with a substantial portion having completed PGY-1 and PGY-2 pharmacy residencies. CCPs were actively involved in patient care, with 86.9% participating in multidisciplinary rounds five days a week. They were engaged in clinical, educational, and administrative activities, with 82.6% involved in retrospective research and educational activities. Furthermore, 78.2% were engaged in pharmacy and therapeutic committees, 56.5% in critical care committees, and 56.5% in pharmacy department policy development. Conclusion: The study reveals that CCPs in SA play integral roles in ICU patient care and contribute significantly to clinical, educational, and administrative activities. The study highlights the need for standardized CCP-to-patient ratios and further support for CCPs to expand their services, thus contributing to enhanced healthcare quality.
- 1 November 2023
- Published by Taylor & Francis in Journal of Multidisciplinary Healthcare
- Vol. ume 16, 3227-3234
Open AccessCharacteristics of Critical Care Pharmacy Services in Saudi Arabia
Purpose: Critical care pharmacists (CCPs) in intensive care units (ICUs) are associated with improved patient outcomes, reduced adverse events (ADEs), and reduced mortality rates. This study aimed to describe the activities and pharmacy services provided by CCP in ICUs in hospitals in Saudi Arabia (SA). Methods: In this cross-sectional prospective study, a questionnaire was electronically sent to CCPs practicing in SA between September 2022 and January 2023. A modified version of a previously published and validated survey was sent to the Saudi Critical Care and Emergency Specialty Network. The questionnaire focused on four CCP activities: clinical, educational, scholarly, and administrative. The level of services was similarly classified into three domains: fundamental, optimal, and desirable. The responses were analyzed using descriptive statistics. Results: The study surveyed 44 CCPs in SA, with a response rate of 52.3%. These CCPs were predominantly located in the central (47.8%) and eastern (30.4%) regions. Hospitals’ ICU bed capacity ranged from 10 to 100, with 82% reporting mixed medical and surgical ICUs. Most CCPs had 4– 10 years of critical care experience, and 60% held advanced degrees, with a substantial portion having completed PGY-1 and PGY-2 pharmacy residencies. CCPs were actively involved in patient care, with 86.9% participating in multidisciplinary rounds five days a week. They were engaged in clinical, educational, and administrative activities, with 82.6% involved in retrospective research and educational activities. Furthermore, 78.2% were engaged in pharmacy and therapeutic committees, 56.5% in critical care committees, and 56.5% in pharmacy department policy development. Conclusion: The study reveals that CCPs in SA play integral roles in ICU patient care and contribute significantly to clinical, educational, and administrative activities. The study highlights the need for standardized CCP-to-patient ratios and further support for CCPs to expand their services, thus contributing to enhanced healthcare quality.
- Open Access
- 1 October 2023
- Published by SAGE Publications in Science Progress
- Vol. 106 (4)
Clonidine safety and effectiveness in the management of suspected paroxysmal sympathetic hyperactivity post-traumatic brain injury: A retrospective cohort study
Introduction: Traumatic brain injury (TBI) is a leading cause of mortality and morbidity worldwide. In addition, TBI may cause paroxysmal sympathetic hyperactivity (PSH), which is associated with poor clinical outcomes. This study aimed to evaluate the safety and effectiveness of clonidine in patients with TBI and suspected PSH. Methods: A retrospective cohort study for critically ill patients with TBI with suspected PSH admitted to intensive care units (ICUs) from 1 May 2016 to 31 January 2020 at a tertiary academic medical center. Eligible patients were categorized based on clonidine use during their ICU stay (Clonidine group vs. Control group). The primary outcome was the improvement in functional outcomes during ICU stay, defined by a delta Glasgow Coma Score (GCS). Secondary outcomes included ICU and hospital length of stay, heart rate variation, and 90-day mortality. Results: A total of 2915 patients were screened, of which 169 were included. Based on multiple regression analysis, patients who received clonidine showed better improvement in functional outcomes by a higher mean delta GCS than patients who did not (Beta Coeff. 0.41; CI: 0.07 – 0.74; P = 0.02). In addition, the patient's GCS upon ICU discharge and IV opioids requirement on day three were higher in the clonidine group than control (beta coefficient (95% CI): 0.18 (0.03, 0.32); p = 0.02 and beta coefficient (95% CI): 1.38 (0.24, 2.52); p = 0.02, respectively). No statistical differences were observed in any of the other secondary outcomes after adjusting for confounders. Conclusion: This study found that patients who received clonidine had better functional outcomes during their ICU stay, as shown by their delta GCS than those who did not. Other outcomes were similar between the groups. More data are needed to explore the role of clonidine in patients with TBI with suspected PSH.
- 1 October 2023
- Published by SAGE Publications in Science Progress
- Vol. 106 (4)
Open AccessClonidine safety and effectiveness in the management of suspected paroxysmal sympathetic hyperactivity post-traumatic brain injury: A retrospective cohort study
Introduction: Traumatic brain injury (TBI) is a leading cause of mortality and morbidity worldwide. In addition, TBI may cause paroxysmal sympathetic hyperactivity (PSH), which is associated with poor clinical outcomes. This study aimed to evaluate the safety and effectiveness of clonidine in patients with TBI and suspected PSH. Methods: A retrospective cohort study for critically ill patients with TBI with suspected PSH admitted to intensive care units (ICUs) from 1 May 2016 to 31 January 2020 at a tertiary academic medical center. Eligible patients were categorized based on clonidine use during their ICU stay (Clonidine group vs. Control group). The primary outcome was the improvement in functional outcomes during ICU stay, defined by a delta Glasgow Coma Score (GCS). Secondary outcomes included ICU and hospital length of stay, heart rate variation, and 90-day mortality. Results: A total of 2915 patients were screened, of which 169 were included. Based on multiple regression analysis, patients who received clonidine showed better improvement in functional outcomes by a higher mean delta GCS than patients who did not (Beta Coeff. 0.41; CI: 0.07 – 0.74; P = 0.02). In addition, the patient's GCS upon ICU discharge and IV opioids requirement on day three were higher in the clonidine group than control (beta coefficient (95% CI): 0.18 (0.03, 0.32); p = 0.02 and beta coefficient (95% CI): 1.38 (0.24, 2.52); p = 0.02, respectively). No statistical differences were observed in any of the other secondary outcomes after adjusting for confounders. Conclusion: This study found that patients who received clonidine had better functional outcomes during their ICU stay, as shown by their delta GCS than those who did not. Other outcomes were similar between the groups. More data are needed to explore the role of clonidine in patients with TBI with suspected PSH.
- Open Access
- 20 May 2023
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 17, 68-75
Clinical pharmacy services in acute care setting during mass gatherings (Hajj): Insights from a task force
- 20 May 2023
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 17, 68-75
Open AccessClinical pharmacy services in acute care setting during mass gatherings (Hajj): Insights from a task force